Roche and Regeneron’s COVID-19 antibody mixture has shown positive results in its Phase III trial, which assessed the investigational treatment in infected non-hospitalised patients.
The primary endpoint of the late-stage outcomes trial of imdevimab and casirivimab in high-risk, non-hospitalized COVID-19 patients was met, with a 70% reduction in the risk of death or hospitalisation at the 1,200mg IV dose level and a 71% reduction at the 2,400mg IV dose level.
“Roche and Regeneron’s COVID-19 antibody mixture has shown positive results in its Phase III trial.“
In addition, the antibody mixture met all critical secondary endpoints in the REGN-COV 2067 trial, including the ability to reduce symptom duration by a median of 4 days.
REGEN-COV20145, a companion phase 2 study in low-risk symptomatic or asymptomatic non-hospitalizedCOVID-19 patients, found substantial and comparable viral load reduction across a range of doses from 300 to 2,400mg.